Spine News and Research

RSS

RTI Biologics reports revenues of $37.8M for first-quarter 2010

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the first quarter ending March 31, 2010

29 Apr 2010

USPTO issues new patent to Applied Spine Technologies

Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".

29 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.

28 Apr 2010

SI-BONE to present iFuse MIS procedure at WCMISST 2010

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint today announced that iFuse initial post-market clinical experience will be presented at upcoming 2010 minimally invasive spine surgery meetings.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Tel Aviv University researcher maps drug target to wipe pain away

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate chronic pain, and as much money is spent by the healthcare system to diagnose what's wrong.

27 Apr 2010

VertiFlex enrolls 100 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 100 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

27 Apr 2010

Global Health Partner reports 12% increase in revenues for first-quarter 2010

The strong growth within our Service Line Bariatrics continues, above all at our oldest clinic Bariatric Center Stockholm. Our arrhythmia clinic Arrhythmia Center Stockholm has also had good capacity utilization during the quarter and continues to generate better than expected results.

26 Apr 2010

McGill researchers receive $1.7M for 10 cutting-edge research projects

Ten McGill University researchers received an important boost today, by way of the announcement of $1.7 million in new funding awarded through the Canada Foundation for Innovation's Leaders Opportunity Fund. "CFI investments are critical for our research leaders, to ensure that their research remains innovative and second to none," said Dr. Rima Rozen, Interim Vice-Principal (Research and International Relations) at McGill.

24 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

Prevention and nonsurgical treatment options to prevent low back pain and protect spine

Back and neck problems can be caused by a herniated disc, spinal stenosis, injury, strain or osteoarthritis. "Although more than 75 percent of Americans will experience some back pain during their lifetime, about 90 percent of cases are resolved without surgery," stated John K. Ratliff, MD, FACS, a Philadelphia spine surgeon and American Association of Neurological Surgeons spokesperson.

24 Apr 2010

Facet Solutions announces data from ACADIA lumbar stenosis pilot study

Facet Solutions, Inc. today announced that it has finished compiling two year data from its lumbar stenosis pilot study in the US. At two years, patients in the ACADIA™ study experienced significant and sustained improvement in Oswestry Disability Index, VAS back pain and VAS leg pain. There were no re-operations in any of the patients, and all patients met the definition of success for ODI improvement.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

FDA grants conditional approval for first approved Total Spine Arthroplasty system clinical study

Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.

23 Apr 2010

Interventional Spine to present at and participate as sponsor of Spine Technology Summit

Interventional Spine, Inc., a privately held medical device manufacturer focusing on diseases of the spine, will present at the Spine Technology Summit at the Roosevelt Hotel in New Orleans on Monday April 26th. This annual event is a showcase for 40 new technology companies and attracts investors, industry, practitioners and analysts.

22 Apr 2010

New Department of Neurosurgery for UNC School of Medicine

The University of North Carolina at Chapel Hill School of Medicine is establishing a new Department of Neurosurgery, effective July 1, 2010.

22 Apr 2010

Merck to market and distribute MBL's Td vaccine in the U.S.

MassBiologics of the University of Massachusetts Medical School and Merck & Co., Inc. announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine.

21 Apr 2010

Surgical treatment for certain injuries helps NFL athletes return to the game faster

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, reports that recent studies indicate that surgical intervention is the best treatment option for certain back injuries.

21 Apr 2010

LDR completes IDE study on Mobi-C cervical artificial disc

LDR, a privately held company with innovative spinal implants for non-fusion and fusion applications, announced completion of the 24-month follow-up phase of its two-level IDE study on the Mobi-C cervical artificial disc. Having previously finalized the 24-month follow-up phase of the one-level study earlier this year, LDR is now the first company to fully enroll and reach two-year follow-up on a concurrent one-level and two-level cervical artificial disc replacement study.

21 Apr 2010